碱烧伤角膜新生血管化的小鼠模型
June 30th, 2023
5.5K views
该方案侧重于碱烧伤诱导的小鼠角膜新生血管形成。该方法生成了可重复和可控的角膜疾病模型，以研究病理性血管生成和相关分子机制，并测试新的药物以预防角膜新生血管形成。
我们正试图开发一种高度可重复的诱导角膜新生血管形成的模型，并确定最相关的组织学和免疫染色方法来监测预防和减少新生血管形成的疗法。角膜碱烧伤模型的缺点是难以控制碱烧伤的面积和严重程度、角膜新生血管的变化以及由于碱溶液过量导致的边缘和组织意外烧伤。角膜新生血管形成是一种威胁部位的疾病。
这种疾病的发病机制知之甚少。该模型将用于获得对病情的新见解，并确定相关的治疗靶点 与角膜袋血管生成模型相比，碱烧伤模型的创建相对简单，也可用于研究角膜炎症、纤维化和上皮增生。与血管生成的角膜缝合模型相比，这些模型与临床化学烧伤的关系也更密切。
我们将使用碱烧伤角膜作为疾病模型，研究一种新的抗血管生成疗法来治疗角膜新生血管形成和混浊。
概述
本研究专注于开发一种可重复的小鼠碱烧伤角膜新生血管模型。该模型旨在阐明病理性血管生成的机制，并评估减轻角膜新生血管的潜在药理学干预措施。
关键研究组成部分
研究领域
- 病理性血管生成
- 角膜疾病
- 药理治疗评估
背景
- 角膜新生血管是对视力的重大威胁。
- 当前对其发病机制的理解有限。
- 现有模型在可重复性和控制方面存在问题。
使用的方法
- 使用氢氧化钠的碱烧伤模型
- C57 Black 6J 雄性小鼠
- 组织学和免疫染色技术用于评估
主要结果
- 碱烧伤角膜与对照组相比新生血管和混浊增加。
- 烧伤组中血管和淋巴管密度更高。
- 通过OCT测量的角膜厚度有显著差异。
结论
- 该模型有助于研究新型抗血管生成疗法。
- 它提供了与临床化学烧伤和角膜愈合相关的见解。
常见问题
什么是角膜新生血管？
角膜新生血管是新血管在角膜中的生长，可能通过引起混浊而威胁视力。
为什么选择碱烧伤模型？
它的创建简单，与其他模型相比更接近临床病例。
这项研究的意义是什么？
这项研究可能会带来新的治疗靶点来治疗角膜新生血管。
烧伤后的恢复需要多长时间？
从手术当天开始监测小鼠，烧伤后10天进行成像以评估新生血管。
免疫染色在研究中的作用是什么？
免疫染色用于量化角膜中的血管和淋巴管密度。
该模型是否适合测试其他药物？
是的，它旨在评估各种旨在减少新生血管的药理学制剂。
减少新生血管的常用方法是什么？
使用这种碱烧伤模型正在研究潜在的抗血管生成疗法。
Executive Industry Relevance
Robust preclinical models for corneal neovascularization are essential for de-risking anti-angiogenic drug discovery and clarifying disease mechanisms. The alkali burn mouse model provides a reproducible, quantifiable system for evaluating therapeutic interventions and understanding pathological angiogenesis in an accessible, avascular tissue. This model supports translational continuity from early discovery through preclinical validation, directly impacting portfolio prioritization for ocular and angiogenesis-targeted programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of angiogenic pathways and identification of therapeutic targets in a controlled in vivo context.
- Supports biological de-risking by modeling clinically relevant chemical injury and its sequelae.
- Facilitates predictive confidence in target engagement and mechanism-of-action studies for anti-angiogenic agents.
Screening & Assay Development
- Provides a standardized, reproducible platform for evaluating candidate compounds and biologics targeting neovascularization.
- Delivers quantitative outputs via immunostaining (CD31, LYVE-1) and OCT imaging for objective assessment.
- Enables assay scalability and cross-study comparability through defined injury parameters and readouts.
Translational & Preclinical Research
- Aligns with disease-relevant injury mechanisms observed in clinical chemical burns.
- Supports continuity from mechanistic discovery to preclinical efficacy and biomarker validation.
- Informs risk-adjusted advancement decisions for ocular and systemic angiogenesis programs.
Pipeline & Workflow Integration
This model bridges early discovery, lead identification, and preclinical validation for anti-angiogenic therapies targeting corneal and extraocular neovascularization.
- Discovery Biology: Enables hypothesis testing and mechanistic de-risking of angiogenesis pathways in vivo.
- Screening: Provides reproducible, quantitative endpoints for compound evaluation and assay standardization.
- Analytics: Supports statistical comparison of neovascularization, lymphangiogenesis, and corneal edema across experimental groups.
- Translational Research: Facilitates biomarker alignment and translational relevance to clinical chemical burn pathology.
- Enterprise Reuse: Offers a reusable, validated platform for ongoing anti-angiogenic drug and biologic screening.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in angiogenesis research.
- Operational Value: Enhances reproducibility, standardization, and scalability of preclinical efficacy studies.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by providing robust in vivo data.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of ocular and angiogenesis-targeted assets.
Implementation Considerations
- Requires expertise in ocular microsurgery and animal handling for consistent injury induction.
- Demands access to immunostaining reagents (anti-CD31, anti-LYVE-1) and OCT imaging infrastructure.
- Necessitates cross-team standardization of injury parameters and scoring criteria for reproducibility.
- Adaptable to various genetic backgrounds and therapeutic modalities with protocol optimization.
- Limitations include potential variability in burn severity and the need for careful procedural control.
Biopharma FAQs
Why does null hypothesis testing matter for alkali burn-induced neovascularization?
Null hypothesis testing enables objective evaluation of whether observed neovascularization differences between treated and control groups are statistically significant, supporting robust target validation and mechanistic de-risking in anti-angiogenic research.
How does independent variable isolation fit the corneal alkali burn pipeline?
Isolating the alkali burn as the independent variable ensures that changes in neovascularization, lymphangiogenesis, and corneal edema can be attributed to the intervention or injury, strengthening the predictive value of preclinical findings.
What do quantitative OCT and immunostaining measurements enable?
Quantitative OCT and immunostaining provide reproducible, objective endpoints for corneal thickness, blood vessel density, and lymphatic vessel density, enabling rigorous comparison of therapeutic efficacy and mechanistic outcomes.
Why are replication requirements critical for cross-functional collaboration?
Replication ensures that neovascularization and therapeutic response data are reliable and transferable across teams, facilitating cross-functional decision-making and portfolio advancement in drug discovery pipelines.
What statistical analysis capabilities are required before implementation?
Robust statistical analysis is needed to compare neovascularization, opacity, and edema scores between groups, validate reproducibility, and support data-driven go/no-go decisions in preclinical development.
